# Theories of cancer: how the ideas connect

Source: https://onco.cc/pathways/theories-of-cancer/  
OnCo record `theories-of-cancer` (Pathway). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Scientists have given more than a dozen answers to what cancer is: mutated genes, runaway evolution, misbehaving stem cells, disordered tissue, ancient cell programmes, broken chromosomes, metabolism, epigenetic switches, unhealed wounds, a failed immune system, ageing tissue, force or electricity. This map shows each theory, who proposed it, what held up, and how the ideas connect.

## Summary

The mainstream trunk runs left to right along the top of the diagram. The somatic mutation theory (cancer starts when one cell accumulates mutations in growth-controlling genes) was refined into the driver and passenger model (only a handful of those mutations matter) and then set in motion by clonal evolution (Nowell 1976: the mutant cell's descendants compete, diversify and are selected, including by treatment). The hallmarks of cancer (Hanahan and Weinberg 2000, 2011, 2022) sit at the end of the trunk as a synthesis: whatever the origin, cancers converge on the same acquired capabilities.

Below the trunk are the theories that challenge or extend it. The aneuploidy theory (Boveri, Duesberg) says broken chromosomes, not point mutations, are the engine; modern work on chromosomal instability and chromothripsis has absorbed it as an accelerator rather than the sole cause. The epigenetic progenitor theory (Feinberg) says the first step is a reversible change in gene regulation, not a mutation, and it feeds the cancer stem cell and plasticity view (Dick, Weissman, Clevers), in which a tumour is a caricature of a tissue with a stem-like compartment that treatment misses. The metabolic theory (Warburg, Seyfried) puts damaged respiration first; its modern reading (Vander Heiden, Thompson) treats metabolic rewiring as a consequence of oncogenic signalling that is nonetheless druggable. The atavistic theory (Davies, Lineweaver, Vincent) frames all of this as a reversion to an ancient unicellular survival programme.

The tissue-level theories occupy the bottom row. The tissue organisation field theory (Sonnenschein and Soto) says cancer is a disease of tissue architecture in which mutations are secondary; the microenvironment and inflammation view (Virchow, Dvorak, Coussens, Bissell) says stroma, vessels and immune cells co-create the tumour; Paget's seed and soil hypothesis applies the same logic to where metastases grow; the immune surveillance and immunoediting theory (Burnet, Thomas, Schreiber) says the immune system continuously removes nascent tumours and sculpts the ones that survive. The ageing tissue view (DeGregori, Martincorena, Ebert) adds time: mutant clones fill normal tissue throughout life and cancer arrives when old tissue changes what is selected. The newest proposals are physical: the mechanical theory (Bissell, Weaver, Jain) treats stiffness and pressure as instructive signals, and the bioelectric theory (Levin) treats membrane voltage patterns as a tissue-level control layer that can override mutations in animal models.

The arrows record how the schools relate. Solid arrows mean one theory feeds another (driver mutations feed clonal evolution; inflammation and immune escape became hallmarks). Inhibiting arrows mean one theory was proposed against another (tissue organisation, aneuploidy, epigenetics, metabolism and bioelectricity were each framed as alternatives to the somatic mutation theory). In practice the field has stopped treating them as rivals: the 2022 hallmarks paper explicitly imports non-mutational epigenetic reprogramming, phenotypic plasticity, the microbiome and senescence, and the somatic mutation theory is now read as necessary but not sufficient.

Status: a scorecard rather than one verdict. Established: somatic mutation theory, driver and passenger model, clonal evolution, immune surveillance and immunoediting, seed and soil, hallmarks as a framework. Partly confirmed: cancer stem cells (real hierarchy in leukaemias, rigid hierarchy replaced by plasticity), epigenetic progenitor theory, aneuploidy and chromosomal instability, metabolic reprogramming, ageing tissue as a field, mechanical theory. Contested: tissue organisation field theory, atavistic theory, bioelectric theory. Superseded: the strong forms of the aneuploidy theory (chromosomes instead of genes) and of the metabolic theory (respiration damage as the origin), and Ewing's purely mechanical account of metastatic spread.

## Fields

- Kind: Pathway
- Last checked: 2026-09-17
- Also known as: theories of carcinogenesis; what is cancer; origin of cancer theories; cancer theory map
- Tags: mechanism; mechanics-atlas; theory
- Analogy: Sixteen detectives arguing over one crime scene. The geneticist blames the suspect's record (mutations), the ecologist blames the neighbourhood that let a small-time offender flourish (evolution and microenvironment), the architect blames the building (tissue organisation), the historian says the suspect is behaving as its ancestors did (atavism), the nutritionist blames what it ate (metabolism), the immunologist asks where the police were (surveillance), and the physicist checks the wiring (mechanics and bioelectricity). The hallmarks paper is the chief inspector's summary: whoever is right about the motive, here is what the culprit always does.
- Interventions: Somatic mutation theory and the driver model gave targeted therapy, genomic profiling, hereditary testing and synthetic lethality (imatinib, osimertinib, olaparib); Clonal evolution gave combination therapy, residual-disease monitoring, rechallenge and adaptive dosing; Immune surveillance and immunoediting gave checkpoint inhibitors, CAR-T, TIL therapy and neoantigen vaccines; The microenvironment and inflammation view gave anti-angiogenics, aspirin chemoprevention and the vaccines against HPV and hepatitis B; seed and soil gave adjuvant bisphosphonates; The metabolic view gave FDG PET and IDH inhibitors; the epigenetic view gave azacitidine, decitabine, EZH2 and menin inhibitors and methylation-based tests; Cancer stem cells and plasticity gave the case for hitting the persister compartment (DLL3 engagers after neuroendocrine transformation); the mechanical view gave stromal decompression and vascular normalisation in trials; the bioelectric and atavistic views have not yet produced a therapy

## Sources

- Wikipedia: https://en.wikipedia.org/wiki/Carcinogenesis
- Sonnenschein and Soto, Theories of carcinogenesis: an emerging perspective (Seminars in Cancer Biology 2008): https://doi.org/10.1016/j.semcancer.2008.03.012
- Hanahan, Hallmarks of Cancer: New Dimensions (Cancer Discovery 2022): https://doi.org/10.1158/2159-8290.CD-21-1059
- Greaves and Maley, Clonal evolution in cancer (Nature 2012): https://doi.org/10.1038/nature10762
- Wikipedia: Carcinogenesis: https://en.wikipedia.org/wiki/Carcinogenesis

## Connected records

- terms: [Ageing tissue and clonal fields: cancer as a disease of old tissue](https://onco.cc/terms/ageing-tissue-field-theory/), [Aneuploidy and chromosomal instability as the cause of cancer](https://onco.cc/terms/aneuploidy-theory-of-cancer/), [Atavistic theory: cancer as a reversion to an ancient programme](https://onco.cc/terms/atavistic-theory-of-cancer/), [Bioelectric theory of cancer (Levin)](https://onco.cc/terms/bioelectric-theory-of-cancer/), [Cancer stem cell theory and phenotypic plasticity](https://onco.cc/terms/cancer-stem-cell-theory/), [Clonal evolution and the ecological view of cancer](https://onco.cc/terms/clonal-evolution-theory/), [Driver and passenger mutations: the refined somatic mutation theory](https://onco.cc/terms/driver-passenger-model/), [Driver mutation](https://onco.cc/terms/driver-mutation/), [Epigenetic progenitor theory: cancer without a first mutation](https://onco.cc/terms/epigenetic-progenitor-theory/), [Hallmarks of Cancer](https://onco.cc/terms/hallmarks-of-cancer/), [Hallmarks of cancer as a synthesis of the theories](https://onco.cc/terms/hallmarks-synthesis/), [Immune surveillance and cancer immunoediting](https://onco.cc/terms/immune-surveillance-immunoediting/), [Inflammation](https://onco.cc/terms/inflammation/), [Mechanical theory: stiffness, pressure and force as causes](https://onco.cc/terms/mechanical-theory-of-cancer/), [Metabolic theory of cancer: from Warburg to oncometabolites](https://onco.cc/terms/metabolic-theory-of-cancer/), [Metastasis](https://onco.cc/terms/metastasis/), [Microenvironment and inflammation: tumours as wounds that do not heal](https://onco.cc/terms/microenvironment-inflammation-theory/), [Seed and soil hypothesis of metastasis (Paget)](https://onco.cc/terms/seed-and-soil-hypothesis/), [Somatic mutation theory of cancer](https://onco.cc/terms/somatic-mutation-theory/), [Tissue organisation field theory (Sonnenschein and Soto)](https://onco.cc/terms/tissue-organisation-field-theory/), [Warburg effect](https://onco.cc/terms/warburg-effect/)
- technologies: [Mathematical models of cancer (mathematical oncology)](https://onco.cc/technologies/mathematical-oncology/)
- pathways: [Cancer metabolism](https://onco.cc/pathways/cancer-metabolism/), [Cancer stem cells & phenotypic plasticity](https://onco.cc/pathways/cancer-stem-cells-plasticity/), [Chromosomal instability & aneuploidy](https://onco.cc/pathways/chromosomal-instability/), [Clonal evolution & minimal residual disease](https://onco.cc/pathways/clonal-evolution/), [Clonal haematopoiesis (CHIP)](https://onco.cc/pathways/clonal-haematopoiesis/), [Drivers, passengers & the two-hit model](https://onco.cc/pathways/oncogene-activation-two-hit/), [Epigenetic reprogramming](https://onco.cc/pathways/epigenetic-reprogramming/), [Epithelial-mesenchymal transition & drug efflux](https://onco.cc/pathways/emt/), [Fibroblast activation, desmoplasia & matrix stiffness](https://onco.cc/pathways/caf-activation-desmoplasia/), [Field cancerisation](https://onco.cc/pathways/field-cancerisation/), [Organ tropism: seed and soil](https://onco.cc/pathways/organ-tropism-seed-soil/), [The cancer-immunity cycle](https://onco.cc/pathways/cancer-immunity-cycle/), [Tumour microenvironment (TME)](https://onco.cc/pathways/tumor-microenvironment/)
- people: [Benjamin L. Ebert](https://onco.cc/people/benjamin-ebert/), [Bert Vogelstein](https://onco.cc/people/bert-vogelstein/), [John E. Dick](https://onco.cc/people/john-dick/), [Matthew Vander Heiden](https://onco.cc/people/matthew-vander-heiden/), [Mel Greaves](https://onco.cc/people/mel-greaves/), [Robert A. Gatenby](https://onco.cc/people/robert-gatenby/), [Robert D. Schreiber](https://onco.cc/people/robert-schreiber/)
- key papers: [Cancer genome landscapes: about 140 driver genes, and each tumour needs only a handful](https://onco.cc/key-papers/paper-vogelstein-cancer-genome-landscapes-science-2013/), [Hallmarks of Cancer 2022: adding phenotypic plasticity, epigenetic reprogramming, microbiomes and senescent cells](https://onco.cc/key-papers/paper-hallmarks-new-dimensions-cancer-discov-2022/), [Schreiber, Old and Smyth 2011: cancer immunoediting](https://onco.cc/key-papers/paper-schreiber-cancer-immunoediting-science-2011/), [The Hallmarks of Cancer: six capabilities every tumour must acquire](https://onco.cc/key-papers/paper-hallmarks-of-cancer-cell-2000/)

---
JSON: https://onco.cc/api/v1/entities/theories-of-cancer.json